Allakos

RSS Feed
Allakos is a clinical stage biotechnology company. The company is developing AK002, its wholly owned monoclonal antibody, for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic esophagitis and mast cell related diseases. AK002 selectively targets both eosinophils and mast cells, white blood cells that are distributed in the body and play a primary role in the inflammatory response. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. As such, AK002 has the potential to treat a number of severe diseases.
  • TickerALLK
  • ISINUS01671P1003
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
GlobeNewsWire

Allakos Appoints Natalie Holles to its Board of Directors

Allakos Appoints Natalie Holles to its Board of Directors REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide valuable insights as we continue to adva...

Free
Corporate Voice
Health Care
Allakos
30d 22/12/2020 1 EN
GlobeNewsWire

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update of its ongoing development activities. Business Updates Announced positive results from our prospective prevalence study showing that 45% (181/405) of symptomatic patients biopsied with...

Free
Corporate Voice
Health Care
Allakos
73d 09/11/2020 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.07
Equity
Real Estate
ALEX , ALLK ...
80d 02/11/2020 22 EN
GlobeNewsWire

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020 Virtual Annual Scientific Meeting. The presentation details were as follows: Title:High Discovery Rate of Previously Undiagnosed Patien...

Free
Corporate Voice
Health Care
Allakos
80d 02/11/2020 1 EN
GlobeNewsWire

Allakos Announces Pricing of Public Offering of Common Stock

Allakos Announces Pricing of Public Offering of Common Stock REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering. The size of the offering is $250 million of shares of its common stock. The Company is offering 3,048,781 shares at a public offering price of $82.00 per share. The offering is expected to close on November 2, 2020, subject to the satisfaction ...

Free
Corporate Voice
Health Care
Allakos
85d 29/10/2020 1 EN
GlobeNewsWire

Allakos Appoints Natalie Holles to its Board of Directors

Allakos Appoints Natalie Holles to its Board of Directors REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide valuable insights as we continue to adva...

Free
Corporate Voice
Health Care
Allakos
30d 22/12/2020 1 EN
GlobeNewsWire

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update of its ongoing development activities. Business Updates Announced positive results from our prospective prevalence study showing that 45% (181/405) of symptomatic patients biopsied with...

Free
Corporate Voice
Health Care
Allakos
73d 09/11/2020 1 EN
GlobeNewsWire

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020 Virtual Annual Scientific Meeting. The presentation details were as follows: Title:High Discovery Rate of Previously Undiagnosed Patien...

Free
Corporate Voice
Health Care
Allakos
80d 02/11/2020 1 EN
GlobeNewsWire

Allakos Announces Pricing of Public Offering of Common Stock

Allakos Announces Pricing of Public Offering of Common Stock REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering. The size of the offering is $250 million of shares of its common stock. The Company is offering 3,048,781 shares at a public offering price of $82.00 per share. The offering is expected to close on November 2, 2020, subject to the satisfaction ...

Free
Corporate Voice
Health Care
Allakos
85d 29/10/2020 1 EN
GlobeNewsWire

Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020

Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020 REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020. The preliminary financial results are subject to finalization of the Company’s customary quarterly financial close process. Allakos estimates that net loss will be between $40.0 million and $50.0 million for the t...

Free
Corporate Voice
Health Care
Allakos
86d 27/10/2020 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.07
Equity
Real Estate
ALEX , ALLK ...
80d 02/11/2020 22 EN
TheScreener

ALLAKOS sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ALLAKOS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date September 11, 2020, the closing price was USD 77.43 and its target price was estimated at USD 51.80.

EUR 12.32
Quant
Health Care
Allakos
132d 12/09/2020 5 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch